Live Breaking News & Updates on Julie Eastland|Page 4

Stay updated with breaking news from Julie eastland. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Harpoon Therapeutics Says AbbVie Declines to Exercise License Option

By Ben Glickman

Harpoon Therapeutics said on Wednesday that AbbVie won t exercise its exclusive license option on Harpoon s HPN217 program.

The South San Francisco, Calif.-based. ....

Ben Glickman , Julie Eastland , South San Francisco , Executive Julie Eastland , Dow Jones ,

Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie - Harpoon Therapeutics (NASDAQ:HARP)

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, announced today that AbbVie has ....

Julie Eastland , Roberth Uhl , Harpoon Therapeutics Inc , Exchange Commission , European Society For Medical Oncology , International Myeloma Society , Option Agreement , Annual Meeting , European Society , Medical Oncology , Activating Construct , Harpoon Therapeutics , Private Securities Litigation Reform Act , Harpoon Therapeutic ,

Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie

Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Julie Eastland , Roberth Uhl , Exchange Commission , European Society For Mdical Oncology , Harpoon Therapeutics Inc , International Myeloma Society , Therapeutics Provides , Option Agreement , Annual Meeting , European Society , Mdical Oncology , Activating Construct , Harpoon Therapeutics , Private Securities Litigation Reform Act , Harpoon Therapeutic ,

Harpoon Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Abstracts for HPN217 and HPN328 accepted for presentations at the International Myeloma Society Annual Meeting and the European Society for Medical Oncology in the fall Enrollment for HPN328 . ....

Julie Eastland , Haibo Wang , Roberth Uhl , International Myeloma Society , Harpoon Therapeutics Inc , Business Development At Amgen , Abbvie Restated Research , Harpoon Development Option Agreement , Exchange Commission , European Society For Medical Oncology , Business Development , Business Development At Hummingbird Bioscience , Annual Meeting , European Society , Medical Oncology , Harpoon Therapeutics , Recent Highlights , Activating Construct , Senior Vice President , Vice President , Five Prime Therapeutics , Development Option Agreement , Discovery Collaboration Agreement , Private Securities Litigation Reform Act , Harpoon Therapeutic , Comprehensive Income ,

Harpoon Therapeutics appoints Haibo Wang as SVP of business development

Wang, who joins Harpoon from Hummingbird Bioscience, has a background of 15 years in biopharma business development and finance. ....

Haibo Wang , Julie Eastland , Luke Walker , Harpoon Therapeutics , Hummingbird Bioscience , Five Prime , Activating Construct ,